Norges Bank
VRDN icon

Norges Bank’s Viridian Therapeutics VRDN Stock Holding History

Norges Bank’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-122,790
Closed -$3.82M – 1365
2025
Q4 		$3.82M Buy
+122,790
New +$3.37M ﹤0.01% 1406
2023
Q2 		– Sell
-208,800
Closed -$5.31M – 2122
2023
Q1 		$5.31M Buy
208,800
+74,600
+56% +$2.39M ﹤0.01% 1736
2022
Q4 		$3.92M Buy
+134,200
New +$3.09M ﹤0.01% 1837

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank's VRDN Position: Q1 2026 in Review

Norges Bank sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 122,790 shares — an estimated $3.82M sold.

Norges Bank first reported a position in VRDN in Q4 2022 and held it in 3 quarters. The position peaked at $5.31M in Q1 2023. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Norges Bank reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Norges Bank sold 122,790 Viridian Therapeutics shares in Q1 2026, an estimated $3.82M.
  • Norges Bank first reported a position in Viridian Therapeutics in Q4 2022 and held it in 3 quarters.
  • Norges Bank's Viridian Therapeutics position peaked at $5.31M in Q1 2023.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.